Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050780 | 0.86 | MAPT (0.61) | SMN1; SMN2KDM4EALDH1A1MAPTTP53 | |
| SCHEMBL4057352 | 0.80 | KMT2A (0.46) | SMN1; SMN2KDM4EALDH1A1MAPTPKM | |
| SCHEMBL11244977 | 0.78 | ALDH1A1 (0.78) | PDE4BSMN1; SMN2KDM4EALDH1A1RXFP1 | |
| Hydrochloric Acid SCHEMBL11254237 | 0.77 | ALDH1A1 (0.80) | PDE4BSMN1; SMN2KDM4EALDH1A1RXFP1 | |
| SCHEMBL23575213 | 0.75 | MAPT (0.81) | SMN1; SMN2KDM4EALDH1A1RXFP1MAPT | |
| SCHEMBL18998183 | 0.75 | AURKB (0.75) | SMN1; SMN2KDM4EALDH1A1RXFP1MAPT | |
| SCHEMBL30864147 | 0.75 | AURKB (0.75) | SMN1; SMN2KDM4EALDH1A1RXFP1MAPT | |
| SCHEMBL3791913 | 0.75 | PAX8 (0.69) | SMN1; SMN2KDM4EALDH1A1RXFP1MAPT | |
| SCHEMBL5325640 | 0.74 | PAX8 (0.85) | SMN1; SMN2KDM4EALDH1A1RXFP1MAPT | |
| SCHEMBL11246546 | 0.74 | TP53 (0.79) | SMN1; SMN2KDM4EALDH1A1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035434-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | claimed |
| US-20080056987-A1 | Quinoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AG (DE) | 2008-03-06 | — | — | US | claimed |
| WO-2007147578-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| EP-2035434-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080056987-A1 | Quinoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AG (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007147578-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056987-A1 | Quinoline derivatives, their preparation, their use, and medicaments comprising them | RECQL, NQO2, XDH | PDE4B 994/4885SMN1; SMN2 3127/4885KDM4E 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.